Analyst: This Biopharm Stock Could Barrel Higher

Just two analysts follow Cerecor

Apr 1, 2019 at 11:21 AM
facebook twitter linkedin

Maryland-based orphan disease specialist Cerecor Inc (NASDAQ:CERC) has flown under the radar of analysts. At last Friday's close, just one analyst covered the biopharmaceutical stock, maintaining a "strong buy" rating and $9 price target.

Earlier today, though, H.C. Wainwright initiated coverage on CERC stock with a "buy" rating, and $11 price target -- a more than 88% premium to last week's settlement at $5.84. This follows news from early March that Cerecor and H.C. Wainwright entered into an underwriting agreement.

In reaction, CERC shares are trading up 0.5% at $5.87, extending a recent bounce off its 50-day moving average, and pacing for a third straight win. Longer term, the equity surged 80.8% in the first quarter, marking its best quarter performance since the fourth quarter of 2017, when it gained 276.4%.

Amid this rally, short sellers have been ramping up their exposure. Short interest jumped 33.9% in the two most recent reporting periods. However, the 352,919 Cerecor shares sold short represents just 1.1% of the equity's available float, or 2.3 times the average daily pace of trading.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!